Veloxis

Veloxis was founded in June 2002, with its headquarters located in Horsholm, Denmark. It is a biotechnology and pharmaceutical company dedicated to the development and commercialization of the immunosuppressant Envarsus XR (LCP-Tacro) to help kidney transplant patients prevent organ rejection. Veloxis is a subsidiary of H. Lundbeck, a Danish pharmaceutical company.